Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine, Inc.filedCriticalNorth American Vaccine, Inc.
Publication of HUP0002359A2publicationCriticalpatent/HUP0002359A2/en
Publication of HUP0002359A3publicationCriticalpatent/HUP0002359A3/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
A substantially pure Haemophilus influenzae type b (Hib) polysaccharide with a refolded meningococcal outer membrane protein (rPorB) conjugate is new. Also claimed are: (a) a method for preparing an Hib polysaccharide-rRorB conjugate; (b) a Hib polysaccharide-rRorB conjugate obtained by the method of (a); (c) a pharmaceutical composition comprising the conjugate; and (d) a method for inducing an immune response to H. influenzae in an animal.
HU0002359A1997-09-081998-07-17Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
HUP0002359A3
(en)
Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof
An antigenic conjugate of hiv major neutralisation determinant covalently linked to purified outer membrane proteosome of neisseria and pharmaceutical compositions